Tags

Type your tag names separated by a space and hit enter

Phenotypic difference of normal plasma cells from mature myeloma cells.
Blood. 1993 May 15; 81(10):2658-63.Blood

Abstract

We have recently shown that two-color analysis with fluorescein isothiocyanate (FITC)-anti-CD38 antibody could clearly distinguish myeloma cells (plasma cells) from other hematopoietic cells in the bone marrow. Myeloma cells (plasma cells) alone were located at CD38strong positive (++) fractions. To further distinguish normal plasma cells from mature myeloma cells phenotypically, we examined immunophenotypes of normal plasma cells and myeloma cells by two-color flow cytometry with FITC-anti-CD38 antibody and phycoerythrin staining with antibody to VLA-4, MPC-1, CD44, CD56, CD19, CD20, CD24, or CD10. Normal plasma cells were all VLA-4+VLA-5+MPC-1+CD44+ CD19+CD56- in the bone marrows from seven healthy donors, tonsils from four patients with chronic tonsillitis, a spleen from one patient with idiopathic thrombocytopenic purpura, and lymph nodes from two patients with chronic lymphadenitis, respectively. On the other hand, mature myeloma cells (12 of 20 cases), VLA-4+VLA-5+MPC-1+, were all CD19- and most of them CD56+, and there were no myeloma cells with the CD19+CD56- phenotype in the 20 cases of myelomas we tested. Thus, as for the expression of CD19 and CD56, normal plasma cells from various tissues are all CD19+CD56-, whereas no myeloma cells have the CD19+CD56- phenotype. According to this finding, we investigated the expression of CD19 and CD56 on plasma cells (CD38++ fractions) in monoclonal gammopathy of undetermined significance (MGUS). Both CD19+CD56- and CD19-DC56+ plasma cells were found in all five cases of MGUS we tested, suggesting that MGUS consists of phenotypically normal plasma cells and myeloma cells. Therefore, it is reasoned that phenotypic analysis of plasma cells with anti-CD19 and anti-CD56 antibodies can distinguish normal plasma cells from malignant plasma cells (myeloma cells), and can detect malignant plasma cells even in MGUS or premyeloma states.

Authors+Show Affiliations

Department of Internal Medicine, Hiroshima University, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8490175

Citation

Harada, H, et al. "Phenotypic Difference of Normal Plasma Cells From Mature Myeloma Cells." Blood, vol. 81, no. 10, 1993, pp. 2658-63.
Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81(10):2658-63.
Harada, H., Kawano, M. M., Huang, N., Harada, Y., Iwato, K., Tanabe, O., Tanaka, H., Sakai, A., Asaoku, H., & Kuramoto, A. (1993). Phenotypic difference of normal plasma cells from mature myeloma cells. Blood, 81(10), 2658-63.
Harada H, et al. Phenotypic Difference of Normal Plasma Cells From Mature Myeloma Cells. Blood. 1993 May 15;81(10):2658-63. PubMed PMID: 8490175.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Phenotypic difference of normal plasma cells from mature myeloma cells. AU - Harada,H, AU - Kawano,M M, AU - Huang,N, AU - Harada,Y, AU - Iwato,K, AU - Tanabe,O, AU - Tanaka,H, AU - Sakai,A, AU - Asaoku,H, AU - Kuramoto,A, PY - 1993/5/15/pubmed PY - 1993/5/15/medline PY - 1993/5/15/entrez SP - 2658 EP - 63 JF - Blood JO - Blood VL - 81 IS - 10 N2 - We have recently shown that two-color analysis with fluorescein isothiocyanate (FITC)-anti-CD38 antibody could clearly distinguish myeloma cells (plasma cells) from other hematopoietic cells in the bone marrow. Myeloma cells (plasma cells) alone were located at CD38strong positive (++) fractions. To further distinguish normal plasma cells from mature myeloma cells phenotypically, we examined immunophenotypes of normal plasma cells and myeloma cells by two-color flow cytometry with FITC-anti-CD38 antibody and phycoerythrin staining with antibody to VLA-4, MPC-1, CD44, CD56, CD19, CD20, CD24, or CD10. Normal plasma cells were all VLA-4+VLA-5+MPC-1+CD44+ CD19+CD56- in the bone marrows from seven healthy donors, tonsils from four patients with chronic tonsillitis, a spleen from one patient with idiopathic thrombocytopenic purpura, and lymph nodes from two patients with chronic lymphadenitis, respectively. On the other hand, mature myeloma cells (12 of 20 cases), VLA-4+VLA-5+MPC-1+, were all CD19- and most of them CD56+, and there were no myeloma cells with the CD19+CD56- phenotype in the 20 cases of myelomas we tested. Thus, as for the expression of CD19 and CD56, normal plasma cells from various tissues are all CD19+CD56-, whereas no myeloma cells have the CD19+CD56- phenotype. According to this finding, we investigated the expression of CD19 and CD56 on plasma cells (CD38++ fractions) in monoclonal gammopathy of undetermined significance (MGUS). Both CD19+CD56- and CD19-DC56+ plasma cells were found in all five cases of MGUS we tested, suggesting that MGUS consists of phenotypically normal plasma cells and myeloma cells. Therefore, it is reasoned that phenotypic analysis of plasma cells with anti-CD19 and anti-CD56 antibodies can distinguish normal plasma cells from malignant plasma cells (myeloma cells), and can detect malignant plasma cells even in MGUS or premyeloma states. SN - 0006-4971 UR - https://www.unboundmedicine.com/medline/citation/8490175/Phenotypic_difference_of_normal_plasma_cells_from_mature_myeloma_cells_ L2 - https://ashpublications.org/blood/article-lookup/doi/&lo.doi; DB - PRIME DP - Unbound Medicine ER -